ClinicalTrials.gg
RecruitingNCT04843865Updated Dec 31, 2024

TCM as an Adjuvant Treatment in Breast Cancer Patients

An interventional study of Chinese Herbs in Breast Cancer and Musculoskeletal Pain, sponsored by Universiti Tunku Abdul Rahman. Recruiting at 1 site in Malaysia. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-31.

Sponsored by Universiti Tunku Abdul Rahman · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Breast Neoplasms with a site in Malaysia — 14 open to participants now, 27 under way, 19 of them phase 3. Breast Neoplasms · Malaysia.

Planned enrollment
55th of 59
30 · median 479
Started
2022
with 3 others
No phase
13 of 62
5 open now
Primary completion
2024-12
later than 3 of 26 live
Registered
39th of 62
by date

Among the 62 studies in Breast Neoplasms with a site in Malaysia, this one is the 55th largest by planned enrollment of the 59 interventional ones that give a count, is one of 4 that started in 2022, is one of 13 with no phase, reaches primary completion later than 3 of the 26 other live ones, and was the 39th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

14 of the 62 studies in Breast Neoplasms with a site in Malaysia are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Malaysia have not opened yet or have stopped. Only those recruiting at a site in Malaysia →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Breast Neoplasms with a site in Malaysia, or all of them as a file.
02

Study summary

Chinese herbs can alleviates the side effects caused by conventional treatment in breast cancer patients and affects the syndrome element differentiation by altering the specific set of proteomes at specific time point of treatment.

Read the detailed description

The previous studies have reported that adjuvant Chinese herbs therapy can improve the survival of breast cancer patients by alleviating the side effects of conventional treatments. Protein expression determines the phenotype of a patient that contributes to the onset of side effects in breast cancer patients caused by conventional treatment. Chinese herbs treatment will alleviate the treatment-related side effects by altering the protein expression in the patients. Associating changes in protein levels with the onset of side effects caused by conventional treatments could be used to identify clinically relevant diagnostic biomarkers. In addition, a set of proteome that is being expressed at diseased state will exhibit the phenotype that is also correlated to the TCM syndrome differentiation. Hence, this study aims to determine the proteome profile for the syndrome differentiation of breast cancer patients treated with adjuvant Chinese herbs for musculoskeletal pain. A quasi-experimental study with purposive sampling will be conducted on 30 breast cancer patients recruited from Tung Shin hospital. All participants will be invited to complete a structured questionnaire to collect their demographic information, pain score, syndrome element differentiation, quality of life, stress, body constitution and other relevant information, including cancer type, cancer stage, and cancer treatment. The questionnaires will be self-administered either at the outpatient waiting room or in the ward of the study hospital. Blood of the patients will be collected for determination of protein expression, biochemical markers and cytokines. The study is an in-point analysis where 2 time-points of data collection and analysis will be carried out at baseline, and immediate post Chinese herbs treatment. Informed consent will be obtained before participant enrolment according to a clinical trial protocol. Statistical differences for protein expression, biochemical markers, cytokines and mean pain score before and after Chinese herbs treatment will be compared using the paired-sample t test.

03

Conditions studied

  • Breast Cancer
  • Musculoskeletal Pain

Keywords

  • Chinese herbs
  • Breast cancer
  • Aromatase inhibitor-associated musculoskeletal symptoms
  • Protein profiling
  • System biology
  • Syndrome element differentiation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women as determined by cessation of menses for at least 1 year or FSH>20 mIU/mL
  • Histology confirmed stage 2 to 3 hormone-receptor positive breast cancer patient
  • Currently taking letrozole for at least 1 month
  • Reported ongoing musculoskeletal pain or stiffness, which started or worsened after initiation of letrozole
  • Had a baseline average pain score over the past week on the Brief Pain Inventory Short Form (BPI-SF) of ≥4 points on a scale of 0 to 10.
  • Completed all indicated surgery, chemotherapy and radiation therapy
  • Agreed to take prescribed Chinese herbs
  • No evidence of distant
  • Follow-up for the duration of the study
  • No acute disease in the past month
  • Able to communicate to practitioner and interviewer
  • Willing to give

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing woman or woman of without effective method of .
  • Patients who default subsequent follow-up/ has irregular follow-up.
  • Patients who directly involved in other study at the same time.
  • History of non-compliance to medical regime and patients who are unwilling or unable to comply with the protocol.
  • Bedridden and/ or cancer to bone/ lung.
  • Concurrent infection requiring intravenous antibiotics
  • History of allergy to Chinese herbs
  • Had previously received Chinese herbs for their AI-induced musculoskeletal symptoms
  • Had received Chinese herbs within one month prior to study entry
  • Current use of or narcotics for pain relief within the past 2 weeks
  • Subjects with acute onset of a chronic illness or with acute disease in the past month or had pre-existing chronic diseases
  • Patients with concomitant severe illness or metastatic disease (poorly controlled hypertension, hypothyroidism, diabetes mellitus, liver diseases, osteoarthritis, rheumatoid arthritis, gout or neuropathic arthropathy, or inflammatory joint disease, bone fracture, stroke)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Chinese Herbs

    Participants received standardized Chinese Herbs treatment orally twice daily for 1 week.

    Dietary Supplement: Chinese Herbs

Interventions

  • Dietary supplementChinese Herbs

    Chinese Herbs

06

What researchers measure

Primary outcomes

  1. Feasibility of the study (Adherence)

    The feasibility of the adherence will be determined by the number of sachets of Chinese herbs taken.

    Time frame: Immediate post 1 week of Chinese Herbs intervention

Secondary outcomes

  1. Feasibility of the study (Dropout rate)

    The feasibility will be assessed by dropout rate of the patients.

    Time frame: Immediate post 1 week of Chinese Herbs intervention

  2. Change in the pain score

    The pain score of breast cancer patients will be assessed by Brief Pain Inventory-Short Form (BPI-SF). BPI-SF is a validated and reliable tool used to assess the severity or intensity of pain on scale ranging from 0 (no pain) to 10 (worst pain imaginable). Higher scores mean a worse outcome.

    Time frame: Baseline and immediate post 1 week of Chinese Herbs intervention

  3. Change in Syndrome element differentiation

    Syndrome Element Differentiation rating scale will be used to determine the syndrome element differentiation of the patients. Syndrome Element Differentiation rating scale can quantify the syndrome elements of this patient based on the clinical manifestations. The quantitative output weight values of syndrome elements are acquired from clinical input data based on the severity and frequency of each sign and symptom. Based on the quantitative output value, the syndrome elements can then be categorized into four levels of health state or severity: normal (\<70), mild (≥ 70 to \<100), moderate (≥100 to \<150), and severe (≥ 150).

    Time frame: Baseline and immediate post 1 week of Chinese Herbs intervention

  4. Change in quality of life as assessed by WHO-BREF (World Health Organization Quality of Life)

    The quality of life will be assessed by the WHO-BREF questionnaire in this study. The WHOQOL-BREF instrument comprises 26 items, measuring the following broad domains: physical health, psychological health, social relationships, and environment, with scores ranging from 0 to 100. The four domain scores denote an individual's perception of the quality of life in each domain. Domain scores are scaled in a positive direction in which higher scores denote a higher quality of life. * the minimum and maximum values: 0, 100 * higher scores mean a better outcome.

    Time frame: Baseline and immediate post 1 week of Chinese Herbs intervention

  5. Change in stress

    The Depression Anxiety Stress Scales (DASS) is a self-report instrument designed to measure the negative emotional states of depression, anxiety and stress. A short version, the DASS 21 scale consists of a list of 21 symptoms with 7 item per scale, each of which is to be rated on a four-point scale of how much you had that symptom in the last week from 'never' to 'most of the time'. In this study, stress will be determined by stress domain of DASS-21 which consists of 7 items.

    Time frame: Baseline and immediate post 1 week of Chinese Herbs intervention

  6. Change in body constitution assessed by Constitution in Chinese Medicine Questionnaire (CCMQ)

    The body constitution will be determined by Constitution in Chinese Medicine Questionnaire (CCMQ). It has 60 items measuring the 9 body constitution types: gentleness, Qi-deficiency, Yang-deficiency, Yin-deficiency, phlegm-wetness, wetness-heat, blood-stasis, Qi-depression, and special diathesis. * the minimum and maximum values: 0, 100 * higher scores mean a worse outcome.

    Time frame: Baseline and immediate post 1 week of Chinese Herbs intervention

  7. Change in protein expression

    The serum proteome will be analyzed by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS).

    Time frame: Baseline and immediate post 1 week of Chinese Herbs intervention

  8. Change in Liver Function Test

    The liver function of the patients will be determined by measuring the alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase.

    Time frame: Baseline and immediate post 1 week of Chinese Herbs intervention

  9. Change in CEA (Carcino-Embryonic Antigen)

    Change in CEA (Carcino-Embryonic Antigen) will be determined by laboratory examination.

    Time frame: Baseline and immediate post 1 week of Chinese Herbs intervention

  10. Change in CRP (C-Reactive Protein)

    Change in CRP (C-Reactive Protein) will be determined by laboratory examination.

    Time frame: Baseline and immediate post 1 week of Chinese Herbs intervention

  11. Change in Progesterone

    Change in Progesterone will be determined by laboratory examination.

    Time frame: Baseline and immediate post 1 week of Chinese Herbs intervention

  12. Change in Estradiol

    Change in Estradiol will be determined by laboratory examination.

    Time frame: Baseline and immediate post 1 week of Chinese Herbs intervention

  13. Change in Cytokine levels of serum

    The cytokines in serum samples of breast cancer patients will be detected by the Quantibody array, multiplexed sandwich enzyme-linked immunosorbent assay (ELISA) based quantitative array platform (Genomax technology) for quantitative measurement of cytokines in human serum. The unit of measurement for the cytokines is the same.

    Time frame: Baseline and immediate post 1 week of Chinese Herbs intervention

07

Study locations

1 of 1 sites recruiting
  • Tung Shin Hospital
    Bukit Bintang, Kuala Lumpur 55100, Malaysia
    Recruiting
08

References and documents

Publications

  • Nie J, Zhao C, Deng LI, Chen J, Yu B, Wu X, Pang P, Chen X. Efficacy of traditional Chinese medicine in treating cancer. Biomed Rep. 2016 Jan;4(1):3-14. doi: 10.3892/br.2015.537. Epub 2015 Nov 5. PubMed 26870326 ↗
  • Sanchez-Vidana DI, Rajwani R, Wong MS. The Use of Omic Technologies Applied to Traditional Chinese Medicine Research. Evid Based Complement Alternat Med. 2017;2017:6359730. doi: 10.1155/2017/6359730. Epub 2017 Jan 31. PubMed 28250795 ↗
  • Wang XS, Mendoza TR, Gao SZ, Cleeland CS. The Chinese version of the Brief Pain Inventory (BPI-C): its development and use in a study of cancer pain. Pain. 1996 Oct;67(2-3):407-16. doi: 10.1016/0304-3959(96)03147-8. PubMed 8951936 ↗
  • Yan E, Song J, Liu C, Hong W. A research on syndrome element differentiation based on phenomenology and mathematical method. Chin Med. 2017 Jul 10;12:19. doi: 10.1186/s13020-017-0141-1. eCollection 2017. PubMed 28702077 ↗
  • Vahedi S. World Health Organization Quality-of-Life Scale (WHOQOL-BREF): Analyses of Their Item Response Theory Properties Based on the Graded Responses Model. Iran J Psychiatry. 2010 Fall;5(4):140-53. PubMed 22952508 ↗
  • Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther. 1995 Mar;33(3):335-43. doi: 10.1016/0005-7967(94)00075-u. PubMed 7726811 ↗
  • Wong W, Lam CL, Wong VT, Yang ZM, Ziea ET, Kwan AK. Validation of the constitution in chinese medicine questionnaire: does the traditional chinese medicine concept of body constitution exist? Evid Based Complement Alternat Med. 2013;2013:481491. doi: 10.1155/2013/481491. Epub 2013 Apr 24. PubMed 23710222 ↗
  • Karpievitch YV, Polpitiya AD, Anderson GA, Smith RD, Dabney AR. Liquid Chromatography Mass Spectrometry-Based Proteomics: Biological and Technological Aspects. Ann Appl Stat. 2010;4(4):1797-1823. doi: 10.1214/10-AOAS341. PubMed 21593992 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Dec 2024, 32 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 32 months is close to that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2021
First posted
Apr 14, 2021
StartActual
Apr 22, 2022
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Dec 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04843865
Lead sponsor
Universiti Tunku Abdul Rahman
Responsible party
Yang Mooi Lim (Professor, Universiti Tunku Abdul Rahman) — Principal investigator
First posted
Apr 14, 2021
Start date
Apr 22, 2022
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Dec 31, 2024

Study contacts

Chin Long Poo
Contact
athrunjoe@gmail.com
0178853596
Yang Mooi Lim
principal investigator · Universiti Tunku Abdul Rahman (UTAR)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion